Jagsonpal Pharmaceuticals Q2 FY27 Results: Key Dates

Board meeting set for October 28

Jagsonpal Pharmaceuticals Ltd is scheduled to consider its unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. The company informed BSE that its board meeting is set for October 28, 2026. The announcement places the September-quarter update at the centre of investor attention after a profitable first quarter of FY27. The board will review both standalone and consolidated numbers. The consolidated presentation is particularly relevant because it includes Aequitas Healthcare following Jagsonpal's acquisition of an 85% stake in July. No Q2 financial outcome was included in the information provided ahead of the board meeting.

Q2 FY27 reporting timeline

The stated upcoming earnings date is October 28, 2026. Jagsonpal has also scheduled an analyst and investor conference call for October 29, 2026, at 2:00 PM IST. Go India Advisors is hosting the call, and Managing Director Manish Gupta is expected to participate. The company said the discussion will cover Q2 FY27 financial results. The trading window has been closed until October 30, according to the investor-feed information. This sequence gives investors a formal board-review date followed by management commentary a day later.

First-quarter revenue reached ₹82 crore

Jagsonpal began FY27 with reported Q1 revenue of about ₹82 crore. The company’s investor feed described this as year-on-year growth of about 9%, while the earnings data showed revenue growth of 8.76% year-on-year and 28.08% quarter-on-quarter. The supplied data put gross profit at ₹15 crore for the quarter. Gross profit increased 27.23% from a year earlier and 70.70% sequentially. Revenue performance was also described as ahead of Indian Pharmaceutical Market growth. These figures form the immediate base for assessing the September-quarter update.

Profit and margin trends in Q1

Q1 net profit stood at ₹13 crore, according to the earnings data. That represented year-on-year growth of 22.15% and quarter-on-quarter growth of 50.46%. Jagsonpal’s investor communication separately said operating EBITDA rose 21% year-on-year to ₹19 crore. It reported an operating EBITDA margin above 23%, an expansion of 240 basis points. The same disclosure put PAT margin at 16%, up 176 basis points from the prior year. Reported first-quarter earnings per share were ₹2.00, compared with ₹1.60 in the comparable prior-year quarter.

Aequitas Healthcare enters consolidated accounts

The September quarter is important because it follows Jagsonpal’s July acquisition of an 85% stake in Aequitas Healthcare. The provided material described the acquisition as bringing first-time hospital-sector consolidation into the company’s results. Consolidated revenue, including Aequitas, was cited at ₹96.4 crore in the related results summary. That summary also referred to like-for-like core growth of 9.3% in Q2. The acquisition makes comparisons between standalone and consolidated results more important for investors. Standalone figures reflect Jagsonpal’s core operations, while consolidated figures include the contribution from the acquired business.

Standalone Q2 and half-year reference figures

The supplied results material cited standalone Q2 revenue of ₹81.38 crore and standalone net profit of ₹12.59 crore. It also stated that first-half standalone revenue and net profit increased from the previous-year period. Standalone EBITDA and PAT for the first half were said to have risen 11.3% and 10.3%, respectively. The material did not provide the absolute first-half revenue, EBITDA or PAT amounts. It also did not specify the comparison-period figures behind these percentage changes. Investors should therefore distinguish those reference numbers from the unaudited Q2 FY27 results due for board consideration on October 28.

Key financial figures at a glance

Wellness business is a further operating factor

Jagsonpal has indicated that contribution from its Wellness business is expected from Q3. The company linked this business line to its stated ₹500 crore FY28 target. The supplied material does not provide a projected quarterly revenue or profit contribution from Wellness. As a result, its impact cannot be quantified from the available disclosures. Still, the Q2 reporting and subsequent management call may offer further clarity on the timing and nature of this contribution. Investors will also be able to assess whether the company provides updated operating commentary alongside the results.

What the results mean for investors

The September-quarter release will show how Jagsonpal’s core growth, margins and acquisition-led consolidation are progressing together. Q1 established revenue growth and a faster increase in net profit than sales. The Q2 update will provide the next confirmed set of standalone and consolidated financial measures after Aequitas was added. It will also allow market participants to compare reported results with the company’s earlier disclosure of ₹96.4 crore in consolidated revenue. The analyst call on October 29 is the scheduled forum for management’s discussion of the quarter. Until the board-approved outcome is released, revenue, profitability and margin expectations for Q2 remain unconfirmed.

Conclusion

Jagsonpal Pharmaceuticals is due to place its Q2 FY27 standalone and consolidated results before the board on October 28, 2026. The update follows Q1 revenue of ₹82 crore, net profit of ₹13 crore and the July acquisition of an 85% stake in Aequitas Healthcare. The following analyst and investor call on October 29 is the next confirmed event for further discussion of the September-quarter performance.